Global C-reactive Protein Testing Market by Disease Area (Lupus, Cancer), by Assay Type (Immunoturbidimetric Assay, ELISA) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

Summary of the Report

Global C-reactive protein testing market was worth USD 5.5 billion in 2020. It is projected to grow at a compound annual rate (CAGR of 0.3%) between 2021 and 2028. The advancements in nanotechnological tools will make it possible to create portable bioanalytical tests with high specificity, sensitivity, quicker response time, multiplexing capabilities, and accurate diagnosis and monitoring onsite.

Because of their flexible optical properties, Plasmonic nanoparticles (PNPs), are one tool that can be used in biosensing applications. In a July 2021 study, researchers from Babe?–Bolyai University in Romania gave an overview of plasmonic nanoparticle-based assays to detect C-reactive proteins (CRP). The study also demonstrated the effectiveness of point-of-care CRP assays. These innovations are expected to increase market growth in the near-term.

In 2020, the market's revenue generation has been boosted by the COVID-19 pandemic. According to NCBI in 2020, researchers at Mohammed VI University of Health Sciences (Morocco) studied C-reactive protein's ability to predict the severity of SARS-CoV-2 infections. Research has shown that CRP levels are a simple, independent and useful factor for predicting infection severity as well as guiding primary care.

C-reactive proteins is a marker that can be used to assess the severity of an infection and prognostication. Chinese guidelines also state that CRP can be used in conjunction with other clinical parameters to evaluate and monitor SARS-CoV-2 infections. Aidian and Abbott offer products that can be used to support the diagnosis of COVID-19 infections.

Aidian, for example, offers QuikRead Go CRP tests that are easy to use and a QuikRead Go portable instrument for measuring C-reactive proteins quantitatively. Abbott also offers Afinion 2 Analyzers and Afinion CRP tests that deliver results in less than 3 minutes. Market growth is expected to be positive due to increased demand for CRP testing in clinical and research settings.

Assay Type Insights

Immunoturbidimetric assays were the dominant market segment and held the largest revenue share at 48.5% in 2020. This segment is expected to grow in the future. This technique is being used in many chronic conditions of the respiratory and cardiac systems. It will be a major driver of the market in the future. The market will grow if the Chemiluminescence immunooassay (CLIA), technique that provides accurate results, is developed.

Market growth is expected to be fueled by technological advancements in immunoturbidimetric tests. Researchers around the globe are involved in developing innovative assays that support accurate and rapid CRP testing. In a January 2021 study, researchers at DM Vasudevan Agappe Diagnostic Limited in India reported that they used a latex-enhanced immuneturbidimetric assay to detect high sensitivity and wide ranges of C-reactive proteins in human serum.

Agappe Diagnostic Limited has created a new reagent to perform this assay. The estimated share is also influenced by the presence of POC devices that are based on this principle. For instance, QuickRead CRP, developed by Orion Diagnostica Oy, is an immunoturbidimetric-based, ready-to-use kit for quantitative detection of CRP levels in plasma, serum, and whole blood samples.

The system is quick and accurate, and was specifically designed for primary healthcare settings. There are also a variety of high-sensitivity, latex-enhanced immunoturbidimetric devices on the market. These innovations are expected to impact the future growth of the field.

Insights on Detection Range

The CRP testing market was dominated by the hsCRP segment, which accounted for 42.8% of the total revenue in 2020. This segment is expected to grow at 0.3% between 2021 and 2028. This test is more precise than standard CRP-based methods and has a lower detection range than conventional methods. High sensitivity CRP can be detected at levels of 10 mgl and >10.0 mg/L.

American Heart Association (AHA), and Centers for Disease Control and Prevention(CDC) state that hs-CRP is an independent marker that aids in the diagnosis of cardiovascular disorders like myocardial injury. A research study on inflammation markers also found a correlation between high levels of hs-CRP and disease activity in rheumatoidarthritis. The study found that a higher serum level of hsCRP could be a biomarker to determine the pathogenesis and severity of rheumatoid.

Market growth will also be boosted by the development of different hsCRP-based POC test devices by market entities. The segment's growth is expected to be driven by technological advancements in traditional CRP methods. Nano-bio hybrid material has been introduced in CRP biosensors as a promising method for accurate and rapid measurement of CRP.

Researchers from Korea published a May 2021 study that summarized the latest advances in electrochemical, optical, and electrical CRP biosensors made of nanomaterial and biomaterial hybrids. These studies will likely increase adoption of advanced CRP tools among end users.

Disease Type Insights

Market leader, Cardiovascular diseases (CVD), accounted for 21.8% of the total revenue in 2020. The market's growth is largely due to an increase in CVDs. CVDs are not caused by sedentary lifestyles, obesity, hypertension, or diabetes. C-reactive proteins is the most widely studied noninvasive biomarker of inflammation in CVDs. There are many hsCRP assays currently on the market.

In 2020, the cancer segment accounted for the second largest revenue share. It is a major public health problem across the globe. The WHO estimates that there are over 1.9 million cancer deaths in Europe every year. This is why it is important to adopt large-scale POC CRP testing solutions for the aid of managing cancer in developing and developed countries.

The rapid spread of COVID-19 has also increased the demand for CRP testing products and services. The revenue generated by other diseases-type segments has seen a 600% increase in revenue from 2019 to 2020. German researchers have created a novel, innovative therapy option that uses CRP.

The study was published in the Journal for Therapeutic Apheresis and Dialysis (June 2020). This therapy option also includes C-reactive Protein Apheresis (for SARS-CoV-2 victims with organ damage). This therapeutic option is extremely risk-free and has a high expected benefit for patients, according to the study.

End-use Insights

In 2020, the hospitals segment was the dominant market. It accounted for 27.2% of the total revenue. The growing use of CRP testing in hospitals in developing countries can explain the growth in the hospital segment. A rise in the incidence of COVID-19 and other cardiovascular diseases, as well as cancer-related infections, has resulted in an increase of hospital visits, which led to the adoption of CRP test kits. This could open up new growth opportunities for the market.

During the analysis period, clinics held a significant market share. The technology of CRP testing has improved over the years, with notable developments in the areas of point-of care and hsCRP. These advances have made it possible to use CRP testing in clinical practice. Clinics will see an increase in CRP testing due to the ongoing COVID-19 epidemic. This is due to the ability of CRP testing to determine the severity of SARS/CoV-2 infection in patients infected.

Regional Insights

North America was the dominant market for C-reactive protein testing and held the largest revenue share at 39.5% in 2020. The market is driven by North America's increasing adoption of advanced technology and a high emphasis on clinical research. Due to the high incidence of cancer in the United States, CRP testing is being used extensively.

According to the American Cancer Society (Acs), prostate cancer is the third most common cancer and the second leading cause of death for men in the United States. According to the same source, one in 41 Americans will be affected by prostate cancer. The Prostate Cancer Foundation states that prostate cancer is the most common non-skin cancer in America. The American Cancer Society and American Urological Association recommend that the PSA test be added to the annual digital rectal exam that millions of American men have in the U.S. This will further drive North American market growth.

Market conditions are expected to improve with the ongoing COVID-19 epidemic. Numerous research studies have been done to assess CRP's prognostic value in COVID-19 sufferers. Researchers from the U.S. published a study in November 2020. This study supports the usefulness of daily CRP values for COVID-19 hospitalized patients. Also, the CRP levels can be used to establish early thresholds. These studies will increase demand for CRP testing within the region.

Market Share Insights & Key Companies

C-reactive protein testing companies are looking to increase their market share by involving key market players in their growth strategies. Boditech Med, Inc., for example, announced plans to double its production capacity in July 2021. The company announced in March 2021 that it would build a new R&D Center at Chuncheon, South Korea, with an investment of USD 6. million. The center will be operational by March 2022. The market leader in C-reactive protein testing is:

• Thermo Fisher Scientific Inc.

• F. Hoffmann-La Roche Ltd.

• Danaher

• Quest Diagnostics

• Siemens Healthineers AG

• Abbott

• Merck KGaAA

• Zoetis

• Ortho Clinical Diagnostics

• Getein Biotech, Inc.

• HORIBA, Ltd

• Randox Laboratories Ltd.

• BODITECH, INC.

• Aidian

Up Market Research published a new report titled “C-reactive Protein Testing Market research report which is segmented by Disease Area (Lupus, Cancer), by Assay Type (Immunoturbidimetric Assay, ELISA), By Players/Companies Danaher, Abbott, Getein Biotech Inc, Aidian, BODITECH MED INC, Zoetis, Siemens Healthineers AG, HORIBA Ltd, Quest Diagnostics, Randox Laboratories Ltd, Ortho Clinical Diagnostics, F Hoffmann-La Roche Ltd, Merck KGaAA, Thermo Fisher Scientific inc”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.

Report Scope

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.

Global C-reactive Protein Testing Market Report Segments:

The market is segmented by Disease Area (Lupus, Cancer), by Assay Type (Immunoturbidimetric Assay, ELISA).

C-reactive Protein Testing Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.

Key Benefits for Industry Participants & Stakeholders:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the C-reactive Protein Testing Market

Overview of the regional outlook of the C-reactive Protein Testing Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.

Highlights of The C-reactive Protein Testing Market Report:

1. The market structure and projections for the coming years.
2. Drivers, restraints, opportunities, and current trends of C-reactive Protein Testing Market.
3. Historical data and forecast.
4. Estimations for the forecast period 2028.
5. Developments and trends in the market.

                1. Lupus

                2. Cancer

                1. Immunoturbidimetric Assay

                2. ELISA

8. Market scenario by region, sub-region, and country.
9. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
10. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
11. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the C-reactive Protein Testing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

How you may use our products:

• Correctly Positioning New Products
• Market Entry Strategies
• Business Expansion Strategies
• Consumer Insights
• Understanding Competition Scenario
• Product & Brand Management
• Channel & Customer Management
• Identifying Appropriate Advertising Appeals

Reasons to Purchase the C-reactive Protein Testing Market Report:

• The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
• Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
• Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
• The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
• Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.